Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Foghorn Therapeutics Inc

FHTX
Current price
4.57 USD +0.08 USD (+1.78%)
Last closed 4.49 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 189 554 768 USD
Yield for 12 month -32.10 %
Week
Month
Year
FHTX
21.11.2021 - 28.11.2021

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 500 Technology Square, Cambridge, MA, United States, 02139

Analytics

WallStreet Target Price

14.25 USD

P/E ratio

Dividend Yield

Current Year

+19 228 000 USD

Last Year

+1 319 000 USD

Current Quarter

+17 478 000 USD

Last Quarter

+5 599 000 USD

Current Year

+19 208 772 USD

Last Year

+1 319 000 USD

Current Quarter

+17 478 000 USD

Last Quarter

+5 599 000 USD

Key Figures FHTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -110 887 000 USD
Operating Margin TTM -97.73 %
PE Ratio
Return On Assets TTM -19.12 %
PEG Ratio
Return On Equity TTM -470.38 %
Wall Street Target Price 14.25 USD
Revenue TTM 32 570 000 USD
Book Value -1.36 USD
Revenue Per Share TTM 0.78 USD
Dividend Share
Quarterly Revenue Growth YOY 163.5 %
Dividend Yield
Gross Profit TTM -86 390 000 USD
Earnings Share -2.46 USD
Diluted Eps TTM -2.46 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics FHTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FHTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation FHTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.9633
Price Sales TTM 5.8199
Enterprise Value EBITDA 0.2265
Price Book MRQ 10.707

Financials FHTX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators FHTX

For 52 weeks

2.84 USD 9.97 USD
50 Day MA 3.99 USD
Shares Short Prior Month 1 355 121
200 Day MA 6.26 USD
Short Ratio 12.18
Shares Short 1 041 252
Short Percent 3.64 %